AbbVie on Thursday reported second-quarter sales and profit that beat expectations as newer immunology drugs delivered the rapid growth needed to offset plunging sales of blockbuster Humira.
Source link
AbbVie on Thursday reported second-quarter sales and profit that beat expectations as newer immunology drugs delivered the rapid growth needed to offset plunging sales of blockbuster Humira.
Source link